Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
Option Care Health (OPCH) Q3 Earnings Preview Amid the Pending Take-Private Deal

Option Care Health (OPCH) Q3 Earnings Preview Amid the Pending Take-Private Deal

Key Takeaways

  • Option Care Health is scheduled to report its third quarter 2026 results, for the period ended September 30, 2026, on November 4, 2026, before the market opens.
  • Consensus estimates point to earnings of approximately $0.44 per share, according to data tracked by EarningsWhispers.
  • The report arrives under unusual circumstances: the company is being acquired by Clayton Dubilier & Rice (CD&R) and McKesson for $32.05 per share and has withdrawn its previously disclosed financial guidance.
  • Management will not host a conference call for the third quarter, removing a key source of forward-looking commentary for investors.
  • Investors will focus on revenue growth, adjusted EBITDA, and margin trends against the backdrop of the pending $5.8 billion take-private transaction.
  • For reference, second quarter 2026 revenue was $1.44 billion, up 1.8% year over year, with diluted earnings per share of $0.35.

Earnings Context and Why It Matters

This quarter is defined less by the income statement than by the transaction reshaping the company. On October 6, 2026, Option Care Health announced a definitive agreement under which CD&R and McKesson will acquire the home and alternate site infusion services provider for $32.05 per share, a roughly 37% premium to its prior close, valuing the company at about $5.8 billion. Because the deal is pending, the company has withdrawn its guidance and will not hold a quarterly call. That makes the reported figures a snapshot of the business ahead of an expected first-half 2027 closing, while investors weigh operating trends against the agreed take-private price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Earnings Expectations

Consensus estimates for the third quarter of 2026 call for earnings of approximately $0.44 per share, according to EarningsWhispers. This compares with diluted earnings per share of $0.35 reported in the second quarter of 2026 and $0.32 in the third quarter of 2025. Analysts will closely track net revenue, which reached $1.44 billion in the second quarter of 2026, reflecting a 1.8% year-over-year increase, as well as adjusted EBITDA and gross margin. In the absence of a conference call and formal guidance, investors will rely on these headline metrics to gauge the company's underlying momentum heading into the pending acquisition. From what I see, these numbers provide the clearest available window into operations right now.

Market Reaction and Investor Sentiment

Sentiment surrounding OPCH is now dominated by the acquisition rather than quarterly fundamentals. Shares jumped roughly 33% in premarket trading after the deal announcement and have since traded near the $32.05 offer price, limiting the usual pre-earnings volatility driven by estimates. Because the transaction sets a known exit value, the third quarter report is unlikely to produce the sharp, estimate-driven swings typical of a standalone company. Instead, investors will watch for any signs of operational deterioration or unexpected weakness that could complicate closing, though the primary risks remain regulatory approvals, stockholder approval, and the deal's anticipated first-half 2027 completion. I'm watching this closely as the focus shifts away from typical earnings beats or misses.

Forward Outlook and Key Factors to Monitor

With formal guidance withdrawn, the forward view centers on the transaction's path to completion rather than multi-quarter operating projections. The deal is expected to close in the first half of calendar year 2027, subject to stockholder approval and regulatory clearances, including antitrust review under the Hart-Scott-Rodino Act and various healthcare filings.

Investors should monitor any updates on the merger timeline and conditions, as delays or required remedies could influence the outcome. On the operational side, watch for trends in revenue growth, gross margin, and adjusted EBITDA in the third quarter release, which will serve as the clearest signal of business health during the pendency period.

Cost and demand dynamics in home and alternate site infusion remain relevant, given the broader shift toward lower-cost, community-based care settings that underpinned the deal's strategic logic. Until the transaction closes, the offer price will continue to anchor the stock, with any deviation reflecting perceived risks to deal completion rather than ordinary earnings performance.

Exploring Tickeron’s AI Tools for This Analysis

In preparing for this earnings release, I turned to Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum indicators and see how OPCH stacks up against peers in the healthcare services space. The platform’s pattern recognition helped highlight how acquisition-related trading has overshadowed typical technical signals lately, which aligns with the muted volatility I expect around the report.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OPCH

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


OPCH sees MACD Histogram just turned negative

OPCH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 26, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 38 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for OPCH moved out of overbought territory on November 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 15 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 73 cases where OPCH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OPCH as a result. In 61 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPCH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

OPCH broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The 50-day moving average for OPCH moved above the 200-day moving average on October 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +0.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPCH advanced for three days, in 175 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

The Aroon Indicator entered an Uptrend today. In 156 of 221 cases where OPCH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OPCH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.763) is normal, around the industry mean (204.532). P/E Ratio (23.797) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (1.101) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (2.688).

The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPCH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 49
Price Growth Rating: 59
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of home and alternate site infusion services.

Industry HospitalNursingManagement

Industry
N/A
Address
3000 Lakeside Drive
Phone
+1 312 940-2443
Employees
8266
Web
https://www.optioncarehealth.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.